Emerging studies suggest this peptide, a dual agonist targeting both the gut-brain axis and glucose-dependent insulinotropic polypeptide , appears to provide a promising advancement for weight treatment. Preliminary human tests have indicated considerable losses in abdominal tissue, possibly surpassing existing body composition treatments. Despi… Read More